Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study

Conference Proceedings

B Solomon, TM Bauer, F De Marinis, E Felip, Y Goto, G Liu, J Mazieres, D-W Kim, T Mok, A Polli, H Thurm, AM Calella, G Peltz, A Shaw

ANNALS OF ONCOLOGY | ELSEVIER | Published : 2020

Pfizer Inc.